Brief Intervention to Reduce Fear of Public Speaking

Social Anxiety Disorder Clinical Trial

Official title:

Brief Intervention to Reduce Fear of Public Speaking

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02790736
• Other study ID #: 7293 (SAD)
• Status: Terminated
• Phase: Phase 4
• Start date: June 2016
• Est. completion date: October 30, 2020

Study information

• Verified date: May 2023
• Source: New York State Psychiatric Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will test the efficacy of propranolol or placebo, administered after retrieval of a previously acquired public speaking fear, in reducing fear and avoidance of public speaking.

Description:

Twenty subjects with Performance-Only type of Social Anxiety Disorder will be enrolled in the study. Participants will complete baseline assessments of fear and avoidance of public speaking. Participants will be randomly assigned to a single dose of propranolol 40mg or placebo, administered immediately after a fear activation procedure. Primary outcome assessment will be self-reported fear of public speaking and avoidance behavior in a behavioral avoidance task 2 weeks after the intervention.

Other known NCT identifiers

• NCT02924610

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: October 30, 2020
• Est. primary completion date: October 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• 18-60 years of age at the time of consent

• Principal Diagnosis of Social Anxiety Disorder, Performance only type

• Has clinically significant fear of public speaking

• Physically healthy

• If female, non-pregnant and not nursing

• Off all psychotropic drug for at least 4 weeks

• A level of understanding sufficient to provide written informed consent to all required study tests and procedures.

Exclusion Criteria:

• History of other serious psychiatric disorder

• Current Major Depressive Disorder

• Presence of developmental disorder or intellectual disability

• SAD patients with SAD not of the performance only type

• Women who are pregnant or nursing

• Current use of psychiatric medication

• Current substance use disorder

• Persons planning to start another treatment during the study period.

• Any significant medical condition that might increase the risk or participation (e.g., seizure disorder, respiratory disorders [e.g., bronchial asthma], cardiovascular disease [e.g., congestive heart failure, heart arrhythmias, sinus bradycardia and greater than first degree block ], low blood pressure [ < 90/60], diabetes, liver or kidney disorders)

• Use of medications that might negatively interact with propranolol (e.g., ACE inhibitors; catecholamine depleting drugs, such as reserpine; calcium channel blockers; digitalis glycosides; haloperidol; chlorpromazine; aluminum hydroxide gel; phenytoin; phenobarbitone; rifampin; antipyrine; lidocaine; cimetidine; theophylline)

Related Conditions & MeSH terms

• Anxiety Disorders
• Phobia, Social
• Social Anxiety Disorder

Intervention

Drug:
• propranolol
active treatment
• Placebo
inactive pill

Locations

Country	Name	City	State
United States	New York State Psychiatric Institute, 1051 Riverside Drive	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
New York State Psychiatric Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Personal Report of Confidence as a Speaker	total score on this self report measure of fear of public speaking. Scored from 0-30, with higher scores indicating better outcome	2 weeks
Secondary	Behavioral Avoidance Task	Up to 5 sequential public speaking challenges, specifically designed for each step to be of increasing difficulty for the individual. Each step is considered completed if subject agrees to try speaking, and speaks for 1 minute. Score is total number of completed steps (0-5) on this 5-step task, with 5 being best	2 weeks